HemCon acquires Alltracel
This article was originally published in The Tan Sheet
Executive SummaryHemCon Medical Technologies completes its cash-for-stock takeover of Alltracel Pharmaceuticals, a Dublin, Ireland-based licensing and distribution firm specializing in cosmeceuticals, nutraceuticals and wound care markets, according to a May 14 release. The deal expands distribution opportunities for HemCon's chitosan-based bandage products used by military and medical first responders, the Portland, Ore.-based wound care firm says. The acquisition also gives HemCon access to Alltracel's nanotechnology-development joint venture with Elmarco and its proprietary Nanospider manufacturing process, which HemCon will leverage "to develop and aggressively grow its market share in acute wound care products," the firm says...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.